Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2744035 | 0.99 | TLR7 (0.70) | TLR7TLR8 | |
| SCHEMBL1951894 | 0.97 | TLR7 (0.77) | TLR7TLR8 | |
| SCHEMBL3862244 | 0.96 | TLR7 (0.75) | TLR7TLR8 | |
| SCHEMBL1952818 | 0.93 | TLR7 (0.64) | TLR7TLR8 | |
| SCHEMBL6719639 | 0.91 | TLR7 (0.71) | TLR7TLR8 | |
| SCHEMBL5746883 | 0.90 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL20796987 | 0.89 | TLR7 (0.62) | TLR7TLR8 | |
| SCHEMBL1043163 | 0.89 | TLR8 (0.74) | TLR7TLR8 | |
| SCHEMBL31027228 | 0.89 | TLR7 (0.62) | TLR7TLR8 | |
| SCHEMBL12971525 | 0.89 | TLR7 (0.65) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-20130225555-A1 | Imidazoquinolines with Immuno-Modulating Properties | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-8436178-B2 | Imidazoquinolines with immuno-modulating properties | ASTRAZENECA AB (SE) | 2013-05-07 | — | — | US | disclosed |
| EP-2507237-A1 | IMIDAZOQUINOLINES WHICH ACT VIA TOLL - LIKE RECEPTORS (TLR) | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| EP-2155743-B1 | IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES | ASTRAZENECA AB (SE) | 2012-08-29 | — | — | EP | disclosed |
| US-8178677-B2 | Hydroxyalkyl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| WO-2011068233-A1 | IMIDAZOQUINOLINES WHICH ACT VIA TOLL - LIKE RECEPTORS (TLR) | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011068233-A1 | IMIDAZOQUINOLINES WHICH ACT VIA TOLL - LIKE RECEPTORS (TLR) | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-06-09 | — | — | WO | disclosed |
| US-20110136801-A1 | Novel Compounds | DAINIPPON SUMITOMO PHARMA CO. LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20100280001-A1 | IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2010-11-04 | — | — | US | disclosed |
| US-20040229897-A1 | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-11-18 | — | — | US | disclosed |
| US-6784188-B2 | ADMINISTERING TO A MAMMAL 1H-IMIDAZO(4,5-C)QUINOLINE RING CONTAINING COMPOUND FOR THE TREATMENT OF DISEASES, INCLUDING VIRAL AND NEOPLSATIC DISEASES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-20040167154-A1 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-26 | — | — | US | disclosed |
| US-20040132762-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-08 | — | — | US | disclosed |
| US-6756382-B2 | SECONDARY AMIDES SUCH AS N-(4-(4-AMINO-2-(2-METHOXYETHYL)-1H-IMIDAZO(4,5-C)QUINOLIN-1-YL)BUTYL)-1 -METHYL-5-OXO-2-PYRIDIN-3-YLPYRROLIDINE-3-CARBOXAMIDE; BIOSYNTHESIS OF CYTOKINES; PROPYLAXIS OF VIRAL DISEASES; IMMUNOLOGY MODULATORS | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-29 | — | — | US | disclosed |
| US-20040106638-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-06-03 | — | — | US | disclosed |
| US-20040019048-A1 | Urea substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-29 | — | — | US | disclosed |
| US-6677349-B1 | INDUCE CYTOKINE BIOSYNTHESIS; ANTICARCINOGENIC AGENTS, VIRICIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-20030144283-A1 | Amide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-07-31 | — | — | US | disclosed |
| US-6573273-B1 | Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain urea, thiourea, acylurea, or sulfonylurea functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can | 3M INNOVATIVE PROPERTIES COMPANY | 2003-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280001-A1 | IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES | IFNG, FCGRT, IFNAR1 | TLR7 267/4885TLR8 1392/4885 |
| US-20040167154-A1 | Urea substituted imidazoquinolines | IFNG, EIF2AK2, IRF3 | TLR7 35/4885TLR8 237/4885 |
| US-20110136801-A1 | Novel Compounds | C1R, RB1, CNKSR1 | TLR7 3566/4885TLR8 4659/4885 |
| US-20040229897-A1 | Amide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 30/4885TLR8 72/4885 |
| US-20040132762-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 59/4885TLR8 71/4885 |
| US-20040019048-A1 | Urea substituted imidazoquinolines | IFNG, EIF2AK2, IRF3 | TLR7 35/4885TLR8 237/4885 |
| US-20130225555-A1 | Imidazoquinolines with Immuno-Modulating Properties | IFNG, FCGRT, IFNAR1 | TLR7 267/4885TLR8 1392/4885 |
| US-20030144283-A1 | Amide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 30/4885TLR8 72/4885 |
| US-20040106638-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 59/4885TLR8 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.